Oramed Pharmaceuticals Inc. announced that it has begun recruitment for its Phase 1 pharmacokinetic (PK) study for ORMD-0901, its oral GLP-1 capsule. This is the first study of ORMD-0901 under Oramed's existing FDA Investigational New Drug application (IND). This is a fully-randomized, single-blind, placebo-controlled, crossover study which will evaluate safety in addition to the pharmacokinetics of ORMD-0901 compared to placebo and to open label Byetta® (a GLP-1 analog currently on the market) in up to 15 healthy subjects. Glucagon-like peptide (GLP-1) analogs, which mimic the natural GLP-1 hormone in the body, are used in the treatment of type 2 diabetes and are currently only available through injection. In a prior Phase 1 study (in Israel) on type 2 diabetic patients, Oramed's ORMD-0901 capsule was well tolerated and showed encouraging efficacy.